Drug Interaction Report

Phenobarbital and Buprenorphine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Phenobarbital

Fidoquel Sezaby
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 219 documented Phenobarbital interactions, 195 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance Effects may be weaker Effects may be stronger
The Bottom Line
Buprenorphine plus phenobarbital is a major interaction: it adds up sedation, breathing, and heart-rhythm risks while also lowering buprenorphine's effectiveness. Keep taking both as prescribed and let your doctor or pharmacist monitor and adjust your doses.

Taking buprenorphine (a pain or opioid-treatment medicine) together with phenobarbital (a seizure and sedative medicine) pulls in two directions at once. Both can slow your breathing and make you very sleepy, so combining them raises the risk of heavy sedation, low blood pressure, and dangerously slow breathing.

At the same time, phenobarbital speeds up how fast your body breaks down buprenorphine, which can make the buprenorphine work less well. Both drugs can also affect your heart's rhythm (the QT interval). This is a serious combination, but your care team can manage it by watching you closely and adjusting doses. Please talk with your doctor or pharmacist before changing anything.

Direction/mechanism: Dual concern. (1) Additive CNS and respiratory depression plus additive QTc prolongation (pharmacodynamic). (2) Phenobarbital induces CYP3A4, increasing buprenorphine clearance and reducing buprenorphine exposure/efficacy (risk of withdrawal or inadequate analgesia).

  • Severity: Major; evidence probable; onset unspecified (induction develops over days to weeks).
  • Monitor: Respiratory depression, sedation, hypotension, opioid withdrawal, and QTc/ECG.
  • Manage: Reserve concurrent use for when alternatives are inadequate. Individualize/adjust buprenorphine dose. On phenobarbital discontinuation, buprenorphine levels rise, raising respiratory-depression risk, so consider a formulation permitting precise titration.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

An increased risk of QT interval prolongation, an increased risk of CNS depression, reduced buprenorphine exposure and reduced efficacy of buprenorphine

Interaction Deep Dive

Taking buprenorphine together with PHENobarbital, or with its prodrug primidone, can cause hypotension, respiratory depression, and severe sedation, which may progress to coma or death. This combination can additionally reduce buprenorphine's effectiveness. When the two must be used together, watch for indications of respiratory depression or opioid withdrawal and weigh the need for dose changes. When PHENobarbital or primidone is stopped, buprenorphine plasma concentrations will rise, and this may amplify or extend both the therapeutic and adverse effects of buprenorphine, including the danger of serious respiratory depression2. If dosing cannot be modified once PHENobarbital is no longer present, switch the patient back to a buprenorphine formulation that allows finer dose titration 1. Prescribing these agents concurrently should be limited to patients for whom other treatment options are insufficient. In addition, using PHENobarbital (an agent that prolongs the QTc interval) alongside other QTc-prolonging agents such as buprenorphine can produce a larger increase in the QTc interval along with the adverse reactions tied to QTc interval prolongation. Where the combination cannot be avoided, monitor patients for a heightened risk of QTc interval prolongation 3.

Why it happens (mechanism)

Additive QT interval prolongation; additive CNS depression; induction of CYP3A4-mediated metabolism of buprenorphine

How to manage this interaction

This combination is used only when other options are not enough, so keep taking both exactly as prescribed unless your prescriber tells you otherwise.

  • Your care team may adjust and individualize your buprenorphine dose and monitor you more closely, including watching your breathing, sedation, blood pressure, and heart rhythm (ECG).
  • Watch for very slow or shallow breathing, extreme drowsiness, confusion, or feeling faint, and get help right away if these occur.
  • Also tell your team if you feel withdrawal or less pain relief, since phenobarbital can lower buprenorphine's effect.
  • If phenobarbital is ever stopped, your buprenorphine dose may need re-checking.

Management is individual — confirm any change with your pharmacist or prescriber.

Literature reports

1 report — tap to read

a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.

Common questions

Can I take Phenobarbital and Buprenorphine together?

Buprenorphine plus phenobarbital is a major interaction: it adds up sedation, breathing, and heart-rhythm risks while also lowering buprenorphine's effectiveness. Keep taking both as prescribed and let your doctor or pharmacist monitor and adjust your doses. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Phenobarbital and Buprenorphine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Phenobarbital and Buprenorphine interaction managed?

This combination is used only when other options are not enough, so keep taking both exactly as prescribed unless your prescriber tells you otherwise. Your care team may adjust and individualize your buprenorphine dose and monitor you more closely, including watching your breathing, sedation, blood pressure, and heart rhythm (ECG). Watch for very slow or shallow breathing, extreme drowsiness, conf… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Phenobarbital or Buprenorphine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (3)

  1. Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
  2. Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
  3. Product Information: SEZABY(TM) intravenous injection, phenobarbital sodium intravenous injection. Sun Pharmaceutical Industries Inc (per manufacturer), Cranbury, NJ, 2022. DailyMed
Was this write-up helpful?
Buprenorphine

Keep reading about Buprenorphine

Phenobarbital

Keep reading about Phenobarbital

Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.